Pervasis Therapeutics, Inc. is developing biologically active therapeutics to address complex diseases and unmet medical needs. With this objective, the company has developed technologies to regulate vascular repair and restore natural blood flow to critical organs. Their flagship product, Vascugel®, which has undergone two Phase II clinical trials, is a cell-based therapeutic matrix developed to reestablish healthy vasculature after vascular injury. Vascugel® has the capability to be delivered in both open surgical and minimally invasive procedures. Clinical data from the two Phase II trials is pending. Additionally, Pervasis is exploring broader indications in non-vascular applications.

Pervasis Therapeutics, Inc.
One Kendall Square
Building 600, 1st Floor
Cambridge, MA 02139

617-621-3407
info@pervasistx.com

News Highlights

August 5, 2008
Pervasis Therapeutics Appoints Frank Litvack, M.D., Former CEO of Conor Medsystems, to its Board of Directors [ PDF ]

May 4, 2008
MIT news
“MIT researchers find novel way to repair airway injuries”

January 15, 2008
Pervasis Therapeutics Closes Additional $9.75 Million in Financing [ PDF ]

September 17, 2007
Pervasis Therapeutics announces New Animal Study Results Supporting Vascugel® in Promoting Healing after Blood Vessel Injury [ PDF ]

View more news